Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SOLIFENACIN SUCCINATE

All products: Limited Use (codes 290)

Other products in the same Health Canada class (G04B, G04BD) — coverage varies; not interchangeable

  • Darifenacin (Enablex): limited Use 290
  • Tolterodine l (Detrol LA): limited Use 290
  • Trospium chloride (Trosec): limited Use 290, Not a benefit
  • Sildenafil (Revatio): not a benefit

Vesicare · DIN 02277263 · 5mg · tablet

Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-21
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Vesicare · DIN 02277263 Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-12-15 Health Canada: Marketed since 2006-06-23 · brand VESICARE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Astellas pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3041 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76292 · Verify on the e-Formulary ↗ (DIN 02277263)

Source record
DIN 02277263: Vesicare Raw flags: sec12=Y, sec3=Y Item: 920000638; group id 960; item number 2279; lccId 00218; manufacturer id ASE Source form: Tab; strength: 5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.6892; ministry $0.3041 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02277263 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76292
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041 Act Solifenacin · DIN 02422239 · $0.3041 Apo-Solifenacin · DIN 02423375 · $0.3041 Auro-Solifenacin · DIN 02446375 · $0.3041 Jamp Solifenacin Succinate · DIN 02428911 · $0.3041 Jamp-Solifenacin · DIN 02424339 · $0.3041 M-Solifenacin Succinate · DIN 02529696 · $0.3041 PMS-Solifenacin · DIN 02417723 · $0.3041 PRZ-Solifenacin · DIN 02493039 · $0.3041 Ran-Solifenacin · DIN 02437988 · $0.3041 Sandoz Solifenacin · DIN 02399032 · $0.3041 Solifenacin · DIN 02458241 · $0.3041 Solifenacin Succinate Tablets · DIN 02448335 · $0.3041 Teva-Solifenacin · DIN 02397900 · $0.3041
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

DARIFENACIN

· 6 products · Limited Use, codes 290 · strengths: 7.5mg, 15mg · ER Tab

TOLTERODINE L-TARTRATE

· 12 products · Limited Use, codes 290 · strengths: 2mg, 4mg, 1mg · SR Cap, Tab

TROSPIUM CHLORIDE

· 3 products · Listed, not a benefit (1), Limited Use, codes 290 (2) · strengths: 20mg · Tab

SILDENAFIL

· 46 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 25mg, 50mg, 100mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: overactive bladder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DARIFENACIN · Limited Use, codes 290 INDICATIONS AND CLINICAL USE ENABLEX (darifenacin) is indicated for the treatment of overactive bladder. PM: https://pdf.hres.ca/dpd_pm/00049667.PDF; date not captured; DIN 02273217; fetched 2026-09-10 Product monograph MIRABEGRON · Limited Use, codes 290 INDICATIONS AND CLINICAL USE MYRBETRIQ (mirabegron) is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00035298.PDF; date June 02, 2016; DIN 02402874; fetched 2026-09-10 Product monograph PROPIVERINE HYDROCHLORIDE · Limited Use, codes 530 INDICATIONS AND CLINICAL USE Mictoryl/Mictoryl Pediatric (propiverine hydrochloride) is indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). PM: https://pdf.hres.ca/dpd_pm/00043480.PDF; date January 15, 2018; DIN 02460289; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE VESICARE® (solifenacin succinate) is indicated for:  Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. Geriatrics: In placebo controlled clinical studies, similar safety and effectiveness were observed between older (623 patients ≥ 65 years and 189 patients ≥ 75 years) and younger patients (1188 patients < 65 years) treated with VESICARE (see ACTION AND CLINICAL PHARMACOLOGY). Pediatrics: Safety and effectiveness in children have not yet been established. https://pdf.hres.ca/dpd_pm/00048963.PDF PM date: December 31, 2018 Source product: VESICARE; DIN 02277263; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.